Here’s what you should know:
1. Year to date, Motus GI reported $11.5 million in net losses, totaling $0.80 per share.
2. A one-time, non-cash warrant expense charge of $3.2 million was included in the year-to-date losses.
3. Despite the losses, Motus has $14.9 million in cash on hand.
4. In the quarter, Motus GI expanded its leadership team, started a new study on its Pure-Vu colonoscopy preparation system and presented data on the Pure-Vu System at Digestive Disease Week 2018, June 2 to June 5 in Washington D.C.
5. Motus plans to commercially launch its Pure-Vu system in the U.S. in 2019.
6. Motus GI CEO Mark Pomeranz said, “We continue to amass a growing body of clinical and health economic data while our market development programs are enabling us to establish strong working relationships with physician champions and their staff within leading institutions who are providing vital, real-time clinical feedback, which we believe will help to accelerate adoption of the Pure-Vu System.”
More articles on gastroenterology:
2 new joint venture ASCs — July/August 2018
Supply chain tip of the day: Take advantage of the cloud
How ASCs can be held liable for 3D medical devices — And 5 strategies to avoid risk
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.